동물 신장질환 시장 규모, 점유율, 동향 분석 : 제품 유형별, 동물 유형별, 투여 경로별, 적응증별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Veterinary Renal Disease Market Growth & Trends:

The global veterinary renal disease market size is anticipated to reach USD 24.85 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 6.7% from 2025 to 2030. Rising prevalence of renal diseases coupled with adoption of therapeutic food as a treatment are key growth drivers for this market. Renal diseases like chronic kidney disease (CKD), renal failure, etc. cause irreversible damage to the renal system of animals. Despite no definite cure for this disease, proper management by various types of therapies can help in the betterment of animal life. One of the most prominent methods is that of nutritional management through therapeutic food.

Another crucial market propeller is the rising adoption of AI in veterinary renal disease diagnostics and treatment. Imaging plays a significant role in veterinary medicine by offering vital data for regular preventative measures as well as the assessment of disease and injury. AI can prove to be a very beneficial tool, especially in radiologist deficient geographies. Associated benefits such as faster and enhanced diagnostic capabilities is anticipated to increase adoption of AI and thereby influence positively on market in near future.

Mars Inc, which is a prominent player in the animal health space, has already stepped into the field of applying AI to veterinary diagnostics and treatment. Antech Diagnostics (Mars Inc.) introduced RenalTech, a cutting-edge diagnostic tool, in 2019. RenalTech uses artificial intelligence (AI) to evaluate pet medical record data and forecast a cat's risk of developing chronic kidney disease (CKD) up to two years ahead of an established clinical diagnosis.

Moreover, market dynamics such as product portfolio expansion, M&A, consolidation activities are further anticipated to provide growth platform to this market. For example, in September 2023, Elanco Animal Health received conditional U.S. FDA approval for Varenzin-CA1 (molidustat oral suspension), as the treatment to control non-regenerative anemia in cats with chronic kidney disease (CKD). Furthermore , in December 2023, Neogen Corporation partnered with the TerraNova Equestrian Center in Myakka City, Florida, making the company the official biosecurity provider of the facility for diagnostic testing products.

Veterinary Renal Disease Market Report Highlights:

• Based on type, the treatment segment led the market with the largest revenue share of 68.96% in 2024, due to the wide array of treatments available coupled with ever growing population of pets globally
• Based on animal type, the feline segment is expected to grow at the fastest CAGR over the forecast period
• Based on route of administration, the oral segment held the largest revenue share in 2024 and the injectable segment is expected to have the fastest CAGR over the forecast period
• Based on the indication, the renal cystitis segment held the largest revenue share of 29.05% in 2024 and nephritis segment is expected to have the second fastest CAGR over the forecast period
• Rising prevalence of a variety of renal complications in animals, prominent usage of pet food, growing disease awareness initiatives are contributing to the market growth
• North America accounted for the largest revenue share of the market in 2024. The increasing significance of animal health care in general throughout the region has been identified as a key factor propelling market expansion. The American Pet Products Association estimates that 65.1 million homes in the country have pets in 2023-2024. Moreover, growing pet owners' awareness of animal health and the significance of providing care for animals with renal disorders are fueling the market expansion in North America
• In May 2024, Dechra Pharmaceuticals announced distribution rights of two products to support kidney health in senior cats - Porus One, and Add One. Porus One contains renaltec, a selective absorber that soaks up precursors of uremia toxins in the cat's intestines that would ordinarily be removed or regulated by healthy kidneys. Add One is a moist cat treat designed for senior cats, developed to encourage them to eat Porus One, and is said to be useful for cats that prefer dry food

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Regional Scope
  • 1.1.2. Estimates And Forecast Timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis
  • 1.6.2. Global Market: CAGR Calculation
• 1.7. Research Scope and Assumptions
  • 1.7.1. List of Secondary Sources
  • 1.7.2. List of Primary Sources
  • 1.7.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Veterinary Renal Disease Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Increasing Prevalence of Renal Diseases
    • 3.2.1.2. Increase in Pet Ownership and Pet Expenditure
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. High treatment cost
    • 3.2.2.2. Limited Access to New Technologies
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenges Analysis
• 3.3. Veterinary Renal Disease Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining Power Of The Suppliers
    • 3.3.1.2. Bargaining Power Of The Buyers
    • 3.3.1.3. Threats Of Substitution
    • 3.3.1.4. Threats From New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental Landscape
    • 3.3.2.5. Legal landscape
• 3.4. Pricing Analysis, 2024
• 3.5. Covid-19 Analysis

Chapter 4. Veterinary Renal Disease Market: Product Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Veterinary Renal Disease Market Movement Analysis
• 4.3. Global Veterinary Renal Disease Market Size & Trend Analysis, by Product Type, 2018 to 2030 (USD Billion)
• 4.4. Diagnosis
  • 4.4.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 4.4.2. Test Kits & Consumables
    • 4.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 4.4.3. Instruments
    • 4.4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
• 4.5. Treatment
  • 4.5.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 4.5.2. Drugs
    • 4.5.2.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 4.5.2.2. NSAIDs
      • 4.5.2.2.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 4.5.2.3. Antibiotics
      • 4.5.2.3.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 4.5.2.4. Cystine-binding Agents
      • 4.5.2.4.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 4.5.2.5. Diuretics
      • 4.5.2.5.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 4.5.2.6. Others
      • 4.5.2.6.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 4.5.3. Therapeutic Food Supplements
    • 4.5.3.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 4.5.4. Ringer Lactate Solution
    • 4.5.4.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Veterinary Renal Disease Market: Animal Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Veterinary Renal Disease Market Movement Analysis
• 5.3. Global Veterinary Renal Disease Market Size & Trend Analysis, by Animal Type, 2018 to 2030 (USD Billion)
• 5.4. Canine
  • 5.4.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
• 5.5. Feline
  • 5.5.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
• 5.6. Bovine
  • 5.6.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
• 5.7. Equine
  • 5.7.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
• 5.8. Others
  • 5.8.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Veterinary Renal Disease Market: Route of Administration Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Veterinary Renal Disease Market Movement Analysis
• 6.3. Global Veterinary Renal Disease Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Billion)
• 6.4. Oral
  • 6.4.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
• 6.5. Injectable
  • 6.5.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Veterinary Renal Disease Market: Indication Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Veterinary Renal Disease Market Movement Analysis
• 7.3. Global Veterinary Renal Disease Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Billion)
• 7.4. Renal Failure
  • 7.4.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
• 7.5. Chronic Kidney Disease (CKD)
  • 7.5.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
• 7.6. Renal Cystitis
  • 7.6.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
• 7.7. Kidney Stones
  • 7.7.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
• 7.8. Neprhritis
  • 7.8.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
• 7.9. Others
  • 7.9.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Veterinary Renal Disease Market: Distribution Channel Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Veterinary Renal Disease Market Movement Analysis
• 8.3. Global Veterinary Renal Disease Market Size & Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Billion)
• 8.4. Veterinary Hospitals & Clinics
  • 8.4.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
• 8.5. Pet Specialty Stores
  • 8.5.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
• 8.6. E-Commerce
  • 8.6.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
• 8.7. Others
  • 8.7.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)

Chapter 9. Veterinary Renal Disease Market: Regional Estimates & Trend Analysis

• 9.1. Regional Dashboard
• 9.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030 North America
• 9.3. North America
  • 9.3.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 9.3.2. U.S.
    • 9.3.2.1. Key Country Dynamics
    • 9.3.2.2. U.S. Veterinary Renal Disease Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.3.3. Canada
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Canada Veterinary Renal Disease Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.3.4. Mexico
    • 9.3.4.1. Key Country Dynamics
    • 9.3.4.2. Mexico Veterinary Renal Disease Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 9.4. Europe
  • 9.4.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 9.4.2. U.K.
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. U.K. Veterinary Renal Disease Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.4.3. Germany
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Germany Veterinary Renal Disease Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.4.4. France
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. France Veterinary Renal Disease Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.4.5. Italy
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Italy Veterinary Renal Disease Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.4.6. Spain
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Spain Veterinary Renal Disease Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.4.7. Sweden
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Sweden Veterinary Renal Disease Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.4.8. Denmark
    • 9.4.8.1. Key Country Dynamics
    • 9.4.8.2. Denmark Veterinary Renal Disease Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.4.9. Norway
    • 9.4.9.1. Key Country Dynamics
    • 9.4.9.2. Norway Veterinary Renal Disease Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 9.5. Asia Pacific
  • 9.5.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 9.5.2. China
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. China Veterinary Renal Disease Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5.3. Japan
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Japan Veterinary Renal Disease Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5.4. India
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. India Veterinary Renal Disease Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5.5. South Korea
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. South Korea Veterinary Renal Disease Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5.6. Australia
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Australia Veterinary Renal Disease Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5.7. Thailand
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Thailand Veterinary Renal Disease Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 9.6. Latin America
  • 9.6.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 9.6.2. Brazil
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Brazil Veterinary Renal Disease Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.6.3. Argentina
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Argentina Veterinary Renal Disease Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 9.7. Middle East and Africa
  • 9.7.1. Market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 9.7.2. Saudi Arabia
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Saudi Arabia Veterinary Renal Disease Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.7.3. South Africa
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. South Africa Veterinary Renal Disease Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.7.4. UAE
    • 9.7.4.1. Key Country Dynamics
    • 9.7.4.2. UAE Veterinary Renal Disease Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.7.5. Kuwait
    • 9.7.5.1. Key Country Dynamics
    • 9.7.5.2. Kuwait Veterinary Renal Disease Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 10. Competitive Landscape

• 10.1. Market Participant Categorization
• 10.2. Company Market Position Analysis/ Heat Map Analysis
• 10.3. Estimated Company Market Share Analysis, 2024
• 10.4. Strategy Mapping
  • 10.4.1. Mergers & Acquisitions
  • 10.4.2. Partnerships & Collaborations
  • 10.4.3. Others
• 10.5. Company Profiles
  • 10.5.1. Mars, Incorporated
    • 10.5.1.1. Participant's Overview
    • 10.5.1.2. Financial Performance
    • 10.5.1.3. Product Type Benchmarking
    • 10.5.1.4. Strategic Initiatives
  • 10.5.2. Nestle Purina PetCare
    • 10.5.2.1. Participant's Overview
    • 10.5.2.2. Financial Performance
    • 10.5.2.3. Product Type Benchmarking
    • 10.5.2.4. Strategic Initiatives
  • 10.5.3. Arkray
    • 10.5.3.1. Participant's Overview
    • 10.5.3.2. Financial Performance
    • 10.5.3.3. Product Type Benchmarking
    • 10.5.3.4. Strategic Initiatives
  • 10.5.4. General Mills
    • 10.5.4.1. Participant's Overview
    • 10.5.4.2. Financial Performance
    • 10.5.4.3. Product Type Benchmarking
    • 10.5.4.4. Strategic Initiatives
  • 10.5.5. Zoetis Inc.
    • 10.5.5.1. Participant's Overview
    • 10.5.5.2. Financial Performance
    • 10.5.5.3. Product Type Benchmarking
    • 10.5.5.4. Strategic Initiatives
  • 10.5.6. Merck & Co., Inc.
    • 10.5.6.1. Participant's Overview
    • 10.5.6.2. Financial Performance
    • 10.5.6.3. Product Type Benchmarking
    • 10.5.6.4. Strategic Initiatives
  • 10.5.7. Elanco
    • 10.5.7.1. Participant's Overview
    • 10.5.7.2. Financial Performance
    • 10.5.7.3. Product Type Benchmarking
    • 10.5.7.4. Strategic Initiatives
  • 10.5.8. Bionote U.S.A
    • 10.5.8.1. Participant's Overview
    • 10.5.8.2. Financial Performance
    • 10.5.8.3. Product Type Benchmarking
    • 10.5.8.4. Strategic Initiatives
  • 10.5.9. Ceva Sante Animale
    • 10.5.9.1. Participant's Overview
    • 10.5.9.2. Financial Performance
    • 10.5.9.3. Product Type Benchmarking
    • 10.5.9.4. Strategic Initiatives
  • 10.5.10. Boehringer Ingelheim International GmbH.
    • 10.5.10.1. Participant's Overview
    • 10.5.10.2. Financial Performance
    • 10.5.10.3. Product Type Benchmarking
    • 10.5.10.4. Strategic Initiatives
  • 10.5.11. Dechra Pharmaceuticals PLC
    • 10.5.11.1. Participant's Overview
    • 10.5.11.2. Financial Performance
    • 10.5.11.3. Product Type Benchmarking
    • 10.5.11.4. Strategic Initiatives
  • 10.5.12. Vedco Inc.
    • 10.5.12.1. Participant's Overview
    • 10.5.12.2. Financial Performance
    • 10.5.12.3. Product Type Benchmarking
    • 10.5.12.4. Strategic Initiatives
  • 10.5.13. Mission Pharmacal Company
    • 10.5.13.1. Participant's Overview
    • 10.5.13.2. Financial Performance
    • 10.5.13.3. Product Type Benchmarking
    • 10.5.13.4. Strategic Initiatives
  • 10.5.14. Neogen Corporation
    • 10.5.14.1. Participant's Overview
    • 10.5.14.2. Financial Performance
    • 10.5.14.3. Product Type Benchmarking
    • 10.5.14.4. Strategic Initiatives
  • 10.5.15. IDEXX Laboratories, Inc.
    • 10.5.15.1. Participant's Overview
    • 10.5.15.2. Financial Performance
    • 10.5.15.3. Product Type Benchmarking
    • 10.5.15.4. Strategic Initiatives

Chapter 11. Key Takeaways